Meeting
2019 Genitourinary Cancers Symposium
Axitinib versus sunitinib as first-line therapies for metastatic renal cell carcinoma: A multicenter retrospective analysis.
Authors
Shingo Hatakeyama
Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Shingo Hatakeyama , Toshiaki Tanaka , Yoshinori Ikehata , Naoki Fujita , Naoya Masumori , Hiroshi Kitamura , Takahiro Yoneyama , Yasuhiro Hashimoto , Chikara Ohyama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 555)
DOI
10.1200/JCO.2019.37.7_suppl.555
Abstract #
555
Poster Bd #
D16
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
First Author: Ilya Tsimafeyeu
Poster
2021 ASCO Annual Meeting
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
First Author: Chun Loo Gan
Poster
2018 Genitourinary Cancers Symposium
Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.
First Author: Sergio Bracarda
Poster
2017 Genitourinary Cancers Symposium
Second line axitinib in metastatic renal cell carcinoma: Evaluation of prognostic factors influencing outcome.
First Author: Helen Brooks